Advancing Continuous Pharmaceutical Manufacturing Offering increased yields, lower utility consumption and reduced waste, continuous manufacturing presents a paradigm shift in drug production and meets the pharmaceutical industry’s demands for faster product development, reduced costs, improved production economics and increased flexibility. The main objective of this review is to examine the existing knowledge, opportunities, challenges, ventures, technological gaps, and quality assurance systems related to continuous pharmaceutical manufacturing from a regulatory standpoint.
Design And Commercialization Of An End To End Continuous Pharmaceutical Over the course of the etp technology lifecycle, the emerging technology team may employ a combination of collaborative approaches to engage with the technology. These examples showed the notable advantages of implementing an end to end continuous manufacturing system in the pharmaceutical sector, from api synthesis to tableting, showcasing its potential to revolutionize the pharmaceutical production workflow. Currently, over 15 pharmaceutical products are manufactured through a continuous process and have obtained approval from the u.s. fda, supported by regulatory frameworks including ich q13,. In japan, shionogi pharma is planning and promoting capital investment to establish a continuous production system for manufacturing processes, investigational drugs, and active pharmaceutical ingredients.
Taking A Collaborative Approach To Continuous Pharmaceutical Manufacturing Currently, over 15 pharmaceutical products are manufactured through a continuous process and have obtained approval from the u.s. fda, supported by regulatory frameworks including ich q13,. In japan, shionogi pharma is planning and promoting capital investment to establish a continuous production system for manufacturing processes, investigational drugs, and active pharmaceutical ingredients. In order to entirely exploit the advantages of cm, the mainly separately developed processes need to be integrated to form end to end systems from the raw materials to the final dosage forms. however, even the integration of two technological steps is a challenging task. The authors describe an ambitious ten‐year collaborative program to invent, design, demonstrate and support commercialization of integrated biopharmaceutical manufacturing technology intended to transform the industry. This article provides a review on the current state of cm implementation, offers insights into life cycle management and regulatory aspects, and explains how a data and knowledge centric approach to risk management can help cm achieve its full potential. Explore how continuous manufacturing is revolutionizing the pharmaceutical industry by streamlining operations, enhancing product quality, and reducing costs.
Comments are closed.